<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481065</url>
  </required_header>
  <id_info>
    <org_study_id>V87P5</org_study_id>
    <nct_id>NCT00481065</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects</brief_title>
  <official_title>A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a
      seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007
      influenza season in the Southern Hemisphere.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine</measure>
    <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
    <description>Seroconversion (serocon.) is defined as negative pre-vaccination serum (titer &lt;10 for HI [Haemagglutination Inhibition], area ≤4 mm^2 for SRH [Single Radial Haemolysis]) / positive post-vaccination titer (titer ≥ 40 for HI, area ≥ 25 mm^2 for SRH).
Significant increase in antibody titer is defined as at least a fourfold increase from non-negative pre-vaccination serum (HI ≥ 10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio After Two or Three Vaccinations of the MF59-eH5N1 Influenza Vaccine</measure>
    <time_frame>21 days after second and third vaccinations (day 22 and day 43)</time_frame>
    <description>Geometric mean Ratio (GMR) was calculated for the haemagglutination inhibition (HI), microneutralization (MN) and single-radial haemolysis (SRH) result as well as the associated 95% confidence intervals. GMR was calculated as 21 days after second and third vaccinations over day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Responded to Two Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain H1N1)</measure>
    <time_frame>21 days after second vaccination (day 43)</time_frame>
    <description>seroconversion: negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Responded to Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain H3N2)</measure>
    <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
    <description>seroconversion (serocon.): negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Responded to Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain B)</measure>
    <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
    <description>seroconversion (serocon.): negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio After Two Doses of the Seasonal eTIV_a Influenza Vaccine (Strain H1N1)</measure>
    <time_frame>21 days after second vaccination (day 43)</time_frame>
    <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio After Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccine (Strain H3N1)</measure>
    <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
    <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio After Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccine (Strain B)</measure>
    <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
    <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Local and Systemic Reactions by Vaccination</measure>
    <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
    <description>The evaluate the safety of the administration of two or three vaccinations of MF59-eH5N1 influenza vaccine, either given sequentially, concomitantly or mixed extemporaneously with seasonal eTIV_a influenza vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Immunogenicity Results After the Booster Vaccination Against the MF59-eH5N1 Influenza Vaccine Mixed Extemporaneously With the Seasonal eTIV_a Influenza Vaccine</measure>
    <time_frame>21 days after booster vaccination (day 403)</time_frame>
    <description>Booster was given on day 382; seroconversion: negative pre-vaccination serum (HI titer &lt;10, SRH area ≤ 4 mm^2)/positive post-vaccination titer (HI titer ≥10) or at least 50% increase in SRH area; Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.
The number of subjects achieving seroconversion or significant increase and seroprotection were calculated at day 382.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio After the Booster Vaccination Against the MF59-eH5N1 Influenza Vaccine Mixed Extemporaneously With the Seasonal eTIV_a Influenza Vaccine</measure>
    <time_frame>21 days after booster vaccination (day 403)</time_frame>
    <description>For each vaccine group, the least squares GMRs were calculated for the HI and SRH results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 382 for all time points for the booster dose.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Pandemic</condition>
  <condition>Avian Influenza</condition>
  <arm_group>
    <arm_group_label>Concomitant alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concomitant +Mixed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concomitant +MF59-eH5N1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed and mixed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed+MF59-eH5N1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF59-eH5N1+eTIV_a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eTIV_a+MF59-eH5N1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH5N1</intervention_name>
    <arm_group_label>Concomitant alone</arm_group_label>
    <arm_group_label>Concomitant +Mixed</arm_group_label>
    <arm_group_label>Concomitant +MF59-eH5N1</arm_group_label>
    <arm_group_label>Mixed</arm_group_label>
    <arm_group_label>Mixed and mixed</arm_group_label>
    <arm_group_label>Mixed+MF59-eH5N1</arm_group_label>
    <arm_group_label>MF59-eH5N1+eTIV_a</arm_group_label>
    <arm_group_label>eTIV_a+MF59-eH5N1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>eTIV_a</intervention_name>
    <arm_group_label>Concomitant alone</arm_group_label>
    <arm_group_label>Concomitant +Mixed</arm_group_label>
    <arm_group_label>Concomitant +MF59-eH5N1</arm_group_label>
    <arm_group_label>Mixed</arm_group_label>
    <arm_group_label>Mixed and mixed</arm_group_label>
    <arm_group_label>Mixed+MF59-eH5N1</arm_group_label>
    <arm_group_label>MF59-eH5N1+eTIV_a</arm_group_label>
    <arm_group_label>eTIV_a+MF59-eH5N1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH5N1 + eTIV_a</intervention_name>
    <arm_group_label>Concomitant alone</arm_group_label>
    <arm_group_label>Concomitant +Mixed</arm_group_label>
    <arm_group_label>Concomitant +MF59-eH5N1</arm_group_label>
    <arm_group_label>Mixed</arm_group_label>
    <arm_group_label>Mixed and mixed</arm_group_label>
    <arm_group_label>Mixed+MF59-eH5N1</arm_group_label>
    <arm_group_label>MF59-eH5N1+eTIV_a</arm_group_label>
    <arm_group_label>eTIV_a+MF59-eH5N1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Drug Information Services +1 800 244 7668</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bogotà</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <results_reference>
    <citation>Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.</citation>
    <PMID>21606530</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <results_first_submitted>August 26, 2011</results_first_submitted>
  <results_first_submitted_qc>January 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2013</results_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bird flu</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>Seasonal influenza vaccine</keyword>
  <keyword>Prepandemic vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 1 center in Colombia.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial. A total of 405 subjects was enrolled and randomized into 8 groups in this study. The participant flow data are from the all randomized set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Concomitant Alone</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="P2">
          <title>Concomitant+Mixed</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="P3">
          <title>Concomitant+MF59-eH5N1</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="P4">
          <title>Mixed</title>
          <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="P5">
          <title>Mixed + Mixed</title>
          <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
        </group>
        <group group_id="P6">
          <title>Mixed+MF59-eH5N1</title>
          <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="P7">
          <title>MF59-eH5N1+eTIV_a</title>
          <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="P8">
          <title>eTIV_a+MF59-eH5N1</title>
          <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="51"/>
                <participants group_id="P7" count="50"/>
                <participants group_id="P8" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="27"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event or death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The demographic characteristics of the randomized population are summarized in this section.</population>
      <group_list>
        <group group_id="B1">
          <title>Concomitant Alone</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B2">
          <title>Concomitant+Mixed</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B3">
          <title>Concomitant+MF59-eH5N1</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B4">
          <title>Mixed</title>
          <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B5">
          <title>Mixed + Mixed</title>
          <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
        </group>
        <group group_id="B6">
          <title>Mixed+MF59-eH5N1</title>
          <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B7">
          <title>MF59-eH5N1+eTIV_a</title>
          <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B8">
          <title>eTIV_a+MF59-eH5N1</title>
          <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="51"/>
            <count group_id="B7" value="50"/>
            <count group_id="B8" value="49"/>
            <count group_id="B9" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="6.2"/>
                    <measurement group_id="B2" value="29.4" spread="5.8"/>
                    <measurement group_id="B3" value="29.5" spread="6.5"/>
                    <measurement group_id="B4" value="29.8" spread="6.8"/>
                    <measurement group_id="B5" value="29.6" spread="6.1"/>
                    <measurement group_id="B6" value="28.8" spread="6.2"/>
                    <measurement group_id="B7" value="27.9" spread="6.2"/>
                    <measurement group_id="B8" value="30.1" spread="6.2"/>
                    <measurement group_id="B9" value="29.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine</title>
        <description>Seroconversion (serocon.) is defined as negative pre-vaccination serum (titer &lt;10 for HI [Haemagglutination Inhibition], area ≤4 mm^2 for SRH [Single Radial Haemolysis]) / positive post-vaccination titer (titer ≥ 40 for HI, area ≥ 25 mm^2 for SRH).
Significant increase in antibody titer is defined as at least a fourfold increase from non-negative pre-vaccination serum (HI ≥ 10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
        <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
        <population>The analysis was done on the full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine</title>
          <description>Seroconversion (serocon.) is defined as negative pre-vaccination serum (titer &lt;10 for HI [Haemagglutination Inhibition], area ≤4 mm^2 for SRH [Single Radial Haemolysis]) / positive post-vaccination titer (titer ≥ 40 for HI, area ≥ 25 mm^2 for SRH).
Significant increase in antibody titer is defined as at least a fourfold increase from non-negative pre-vaccination serum (HI ≥ 10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
          <population>The analysis was done on the full analysis set (FAS).</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI seroprot. (day1) N=46,48,47,50,49,48,48,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI serocon. (2nd vacc) N=46,48,46,49,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="14" upper_limit="41"/>
                    <measurement group_id="O2" value="33" lower_limit="54" upper_limit="81"/>
                    <measurement group_id="O3" value="37" lower_limit="66" upper_limit="91"/>
                    <measurement group_id="O4" value="13" lower_limit="15" upper_limit="41"/>
                    <measurement group_id="O5" value="31" lower_limit="49" upper_limit="78"/>
                    <measurement group_id="O6" value="34" lower_limit="56" upper_limit="83"/>
                    <measurement group_id="O7" value="19" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="O8" value="22" lower_limit="35" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprot. (2nd vacc) N=46,48,46,49,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="14" upper_limit="41"/>
                    <measurement group_id="O2" value="34" lower_limit="56" upper_limit="83"/>
                    <measurement group_id="O3" value="37" lower_limit="66" upper_limit="91"/>
                    <measurement group_id="O4" value="14" lower_limit="17" upper_limit="43"/>
                    <measurement group_id="O5" value="32" lower_limit="52" upper_limit="80"/>
                    <measurement group_id="O6" value="34" lower_limit="56" upper_limit="83"/>
                    <measurement group_id="O7" value="19" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="O8" value="22" lower_limit="35" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI serocon. (3rd vacc) N=23,24,36,39,31,20,32,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="52" upper_limit="90"/>
                    <measurement group_id="O2" value="15" lower_limit="39" upper_limit="79"/>
                    <measurement group_id="O3" value="26" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="O4" value="19" lower_limit="37" upper_limit="71"/>
                    <measurement group_id="O5" value="16" lower_limit="43" upper_limit="82"/>
                    <measurement group_id="O6" value="13" lower_limit="41" upper_limit="85"/>
                    <measurement group_id="O7" value="24" lower_limit="67" upper_limit="96"/>
                    <measurement group_id="O8" value="16" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprot. (3rd vacc) N=24,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="53" upper_limit="90"/>
                    <measurement group_id="O2" value="15" lower_limit="39" upper_limit="79"/>
                    <measurement group_id="O3" value="26" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="O4" value="20" lower_limit="39" upper_limit="74"/>
                    <measurement group_id="O5" value="16" lower_limit="43" upper_limit="82"/>
                    <measurement group_id="O6" value="14" lower_limit="46" upper_limit="88"/>
                    <measurement group_id="O7" value="24" lower_limit="67" upper_limit="96"/>
                    <measurement group_id="O8" value="16" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH seroprot. (day 1) N=46,48,47,50,49,48,48,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH serocon. (2nd vacc) N=46,48,46,50,46,48,47,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="18" upper_limit="46"/>
                    <measurement group_id="O2" value="38" lower_limit="65" upper_limit="90"/>
                    <measurement group_id="O3" value="43" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O4" value="11" lower_limit="12" upper_limit="37"/>
                    <measurement group_id="O5" value="31" lower_limit="52" upper_limit="80"/>
                    <measurement group_id="O6" value="38" lower_limit="67" upper_limit="91"/>
                    <measurement group_id="O7" value="23" lower_limit="34" upper_limit="64"/>
                    <measurement group_id="O8" value="25" lower_limit="43" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH seroprot. (2nd vacc) N=46,48,46,50,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="O2" value="40" lower_limit="70" upper_limit="93"/>
                    <measurement group_id="O3" value="43" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O4" value="14" lower_limit="16" upper_limit="42"/>
                    <measurement group_id="O5" value="35" lower_limit="58" upper_limit="85"/>
                    <measurement group_id="O6" value="42" lower_limit="75" upper_limit="95"/>
                    <measurement group_id="O7" value="26" lower_limit="40" upper_limit="70"/>
                    <measurement group_id="O8" value="29" lower_limit="51" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH serocon. (3rd vacc) N=25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="20" lower_limit="59" upper_limit="93"/>
                    <measurement group_id="O3" value="27" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O4" value="27" lower_limit="54" upper_limit="85"/>
                    <measurement group_id="O5" value="12" lower_limit="28" upper_limit="69"/>
                    <measurement group_id="O6" value="12" lower_limit="36" upper_limit="81"/>
                    <measurement group_id="O7" value="18" lower_limit="44" upper_limit="81"/>
                    <measurement group_id="O8" value="16" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH seroprot. (3rd vacc) N=25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O2" value="21" lower_limit="64" upper_limit="95"/>
                    <measurement group_id="O3" value="27" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O4" value="27" lower_limit="60" upper_limit="90"/>
                    <measurement group_id="O5" value="11" lower_limit="24" upper_limit="65"/>
                    <measurement group_id="O6" value="15" lower_limit="51" upper_limit="91"/>
                    <measurement group_id="O7" value="23" lower_limit="63" upper_limit="94"/>
                    <measurement group_id="O8" value="19" lower_limit="55" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN ≥40 (day 1) N=46,48,47,50,49,48,48,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN ≥40 (2nd vacc) N=46,48,46,50,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="18" upper_limit="46"/>
                    <measurement group_id="O2" value="36" lower_limit="60" upper_limit="86"/>
                    <measurement group_id="O3" value="44" lower_limit="85" upper_limit="99"/>
                    <measurement group_id="O4" value="16" lower_limit="20" upper_limit="47"/>
                    <measurement group_id="O5" value="36" lower_limit="60" upper_limit="86"/>
                    <measurement group_id="O6" value="44" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O7" value="24" lower_limit="36" upper_limit="66"/>
                    <measurement group_id="O8" value="20" lower_limit="31" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN ≥40 (3rd vacc) N=25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="24" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O3" value="28" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O4" value="31" lower_limit="73" upper_limit="97"/>
                    <measurement group_id="O5" value="22" lower_limit="69" upper_limit="97"/>
                    <measurement group_id="O6" value="20" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O7" value="26" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="O8" value="23" lower_limit="74" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio After Two or Three Vaccinations of the MF59-eH5N1 Influenza Vaccine</title>
        <description>Geometric mean Ratio (GMR) was calculated for the haemagglutination inhibition (HI), microneutralization (MN) and single-radial haemolysis (SRH) result as well as the associated 95% confidence intervals. GMR was calculated as 21 days after second and third vaccinations over day 1.</description>
        <time_frame>21 days after second and third vaccinations (day 22 and day 43)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After Two or Three Vaccinations of the MF59-eH5N1 Influenza Vaccine</title>
          <description>Geometric mean Ratio (GMR) was calculated for the haemagglutination inhibition (HI), microneutralization (MN) and single-radial haemolysis (SRH) result as well as the associated 95% confidence intervals. GMR was calculated as 21 days after second and third vaccinations over day 1.</description>
          <population>Full analysis set (FAS)</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI (2nd vacc) N= 46,48,46,49,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="1.29" upper_limit="3.46"/>
                    <measurement group_id="O2" value="12" lower_limit="7.09" upper_limit="19"/>
                    <measurement group_id="O3" value="23" lower_limit="14" upper_limit="37"/>
                    <measurement group_id="O4" value="2.16" lower_limit="1.33" upper_limit="3.49"/>
                    <measurement group_id="O5" value="9.52" lower_limit="5.86" upper_limit="15"/>
                    <measurement group_id="O6" value="14" lower_limit="8.32" upper_limit="22"/>
                    <measurement group_id="O7" value="2.96" lower_limit="1.81" upper_limit="4.86"/>
                    <measurement group_id="O8" value="5.34" lower_limit="3.2" upper_limit="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI (3rd vacc) N= 24,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="15" upper_limit="76"/>
                    <measurement group_id="O2" value="17" lower_limit="7.82" upper_limit="37"/>
                    <measurement group_id="O3" value="93" lower_limit="44" upper_limit="197"/>
                    <measurement group_id="O4" value="10" lower_limit="5.36" upper_limit="20"/>
                    <measurement group_id="O5" value="9.89" lower_limit="4.5" upper_limit="22"/>
                    <measurement group_id="O6" value="21" lower_limit="8.56" upper_limit="49"/>
                    <measurement group_id="O7" value="66" lower_limit="31" upper_limit="139"/>
                    <measurement group_id="O8" value="12" lower_limit="5.53" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH (2nd vacc) N= 46,48,46,49,46,47,47,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="1.35" upper_limit="2.44"/>
                    <measurement group_id="O2" value="5.32" lower_limit="3.98" upper_limit="7.09"/>
                    <measurement group_id="O3" value="9.64" lower_limit="7.17" upper_limit="13"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.19" upper_limit="2.11"/>
                    <measurement group_id="O5" value="4.25" lower_limit="3.16" upper_limit="5.71"/>
                    <measurement group_id="O6" value="6.04" lower_limit="4.5" upper_limit="8.11"/>
                    <measurement group_id="O7" value="2.9" lower_limit="2.16" upper_limit="3.88"/>
                    <measurement group_id="O8" value="3.26" lower_limit="2.39" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH (3rd vacc) N= 25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" lower_limit="6.73" upper_limit="15"/>
                    <measurement group_id="O2" value="6.22" lower_limit="4.25" upper_limit="9.12"/>
                    <measurement group_id="O3" value="11" lower_limit="7.47" upper_limit="16"/>
                    <measurement group_id="O4" value="5.13" lower_limit="3.69" upper_limit="7.13"/>
                    <measurement group_id="O5" value="3.1" lower_limit="2.07" upper_limit="4.65"/>
                    <measurement group_id="O6" value="6.76" lower_limit="4.33" upper_limit="11"/>
                    <measurement group_id="O7" value="7.17" lower_limit="4.95" upper_limit="10"/>
                    <measurement group_id="O8" value="4.55" lower_limit="3.08" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN (2nd vacc) N= 46,48,47,50,49,48,48,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.54" upper_limit="2.91"/>
                    <measurement group_id="O2" value="7.64" lower_limit="5.61" upper_limit="10"/>
                    <measurement group_id="O3" value="13" lower_limit="9.45" upper_limit="18"/>
                    <measurement group_id="O4" value="2.15" lower_limit="1.59" upper_limit="2.92"/>
                    <measurement group_id="O5" value="6.79" lower_limit="4.98" upper_limit="9.26"/>
                    <measurement group_id="O6" value="11" lower_limit="8.04" upper_limit="15"/>
                    <measurement group_id="O7" value="3.86" lower_limit="2.82" upper_limit="5.29"/>
                    <measurement group_id="O8" value="3.49" lower_limit="2.52" upper_limit="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN (3rd vacc) N= 24,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="23" upper_limit="64"/>
                    <measurement group_id="O2" value="39" lower_limit="23" upper_limit="64"/>
                    <measurement group_id="O3" value="66" lower_limit="40" upper_limit="109"/>
                    <measurement group_id="O4" value="16" lower_limit="10" upper_limit="25"/>
                    <measurement group_id="O5" value="13" lower_limit="8" upper_limit="23"/>
                    <measurement group_id="O6" value="23" lower_limit="13" upper_limit="41"/>
                    <measurement group_id="O7" value="58" lower_limit="36" upper_limit="95"/>
                    <measurement group_id="O8" value="21" lower_limit="12" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Local and Systemic Reactions by Vaccination</title>
        <description>The evaluate the safety of the administration of two or three vaccinations of MF59-eH5N1 influenza vaccine, either given sequentially, concomitantly or mixed extemporaneously with seasonal eTIV_a influenza vaccine.</description>
        <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Local and Systemic Reactions by Vaccination</title>
          <description>The evaluate the safety of the administration of two or three vaccinations of MF59-eH5N1 influenza vaccine, either given sequentially, concomitantly or mixed extemporaneously with seasonal eTIV_a influenza vaccine.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=31,33,36,39,31,29,34,31) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=31,33,36,39,31,29,34,31) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=31,33,36,39,31,29,34,31) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis (N=31,33,36,39,31,29,34,31) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=31,33,36,39,31,29,34,31) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever≥ 38°C (N=50,48,47,51,48,47,47,43) 2nd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Vaccine was not administered on this date.</measurement>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=31,49,36,39,31,50,34,49) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=31,33,36,39,31,29,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=30,33,36,39,31,29,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=31,33,36,39,31,29,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=31,32,36,39,31,29,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=31,49,36,39,51,29,49,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=31,33,36,39,31,50,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=31,33,36,39,31,50,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever≥ 38°C (N=31,48,47,51,48,29,34,32) 3rd vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Responded to Two Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain H1N1)</title>
        <description>seroconversion: negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
        <time_frame>21 days after second vaccination (day 43)</time_frame>
        <population>The analysis was done on the full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Responded to Two Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain H1N1)</title>
          <description>seroconversion: negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
          <population>The analysis was done on the full analysis set (FAS).</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI seroprot. (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroconversion N=46,48,46,49,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="57" upper_limit="84"/>
                    <measurement group_id="O2" value="35" lower_limit="58" upper_limit="85"/>
                    <measurement group_id="O3" value="36" lower_limit="64" upper_limit="89"/>
                    <measurement group_id="O4" value="29" lower_limit="43" upper_limit="72"/>
                    <measurement group_id="O5" value="37" lower_limit="63" upper_limit="88"/>
                    <measurement group_id="O6" value="37" lower_limit="63" upper_limit="88"/>
                    <measurement group_id="O7" value="29" lower_limit="46" upper_limit="75"/>
                    <measurement group_id="O8" value="31" lower_limit="56" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprotection N=46,48,46,49,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="66" upper_limit="91"/>
                    <measurement group_id="O2" value="45" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O3" value="43" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O4" value="39" lower_limit="64" upper_limit="88"/>
                    <measurement group_id="O5" value="44" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O6" value="41" lower_limit="72" upper_limit="94"/>
                    <measurement group_id="O7" value="43" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O8" value="40" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Responded to Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain H3N2)</title>
        <description>seroconversion (serocon.): negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
        <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
        <population>The analysis was done on the full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Responded to Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain H3N2)</title>
          <description>seroconversion (serocon.): negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
          <population>The analysis was done on the full analysis set (FAS).</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI seroprot. (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI serocon. (2nd vacc) N=46,48,46,49,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="35" upper_limit="65"/>
                    <measurement group_id="O2" value="36" lower_limit="60" upper_limit="86"/>
                    <measurement group_id="O3" value="35" lower_limit="61" upper_limit="87"/>
                    <measurement group_id="O4" value="35" lower_limit="55" upper_limit="82"/>
                    <measurement group_id="O5" value="40" lower_limit="70" upper_limit="93"/>
                    <measurement group_id="O6" value="40" lower_limit="70" upper_limit="93"/>
                    <measurement group_id="O7" value="35" lower_limit="60" upper_limit="86"/>
                    <measurement group_id="O8" value="29" lower_limit="51" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprot. (2nd vacc) N=46,48,46,50,48,48,47,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="71" upper_limit="94"/>
                    <measurement group_id="O2" value="46" lower_limit="86" upper_limit="99"/>
                    <measurement group_id="O3" value="44" lower_limit="85" upper_limit="99"/>
                    <measurement group_id="O4" value="49" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O5" value="48" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O6" value="48" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O7" value="47" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O8" value="40" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI serocon. (3rd vacc) N=25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="55" upper_limit="91"/>
                    <measurement group_id="O2" value="20" lower_limit="59" upper_limit="93"/>
                    <measurement group_id="O3" value="26" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="O4" value="30" lower_limit="70" upper_limit="95"/>
                    <measurement group_id="O5" value="18" lower_limit="51" upper_limit="88"/>
                    <measurement group_id="O6" value="17" lower_limit="62" upper_limit="97"/>
                    <measurement group_id="O7" value="25" lower_limit="72" upper_limit="98"/>
                    <measurement group_id="O8" value="21" lower_limit="64" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprot. (3rd vacc) N=30,33,36,39,31,29,34,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="53" upper_limit="90"/>
                    <measurement group_id="O2" value="15" lower_limit="39" upper_limit="79"/>
                    <measurement group_id="O3" value="26" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="O4" value="20" lower_limit="39" upper_limit="74"/>
                    <measurement group_id="O5" value="16" lower_limit="43" upper_limit="82"/>
                    <measurement group_id="O6" value="14" lower_limit="46" upper_limit="88"/>
                    <measurement group_id="O7" value="86" lower_limit="67" upper_limit="96"/>
                    <measurement group_id="O8" value="64" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Responded to Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain B)</title>
        <description>seroconversion (serocon.): negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
        <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
        <population>The analysis was done on the full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Responded to Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccines (Strain B)</title>
          <description>seroconversion (serocon.): negative pre-vaccination serum (HI titer &lt;10, SRH area =&lt;4 mm^2)/positive post-vaccination titer (HI titer =&gt;10) or at least 50% increase in the SRH area.
Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.</description>
          <population>The analysis was done on the full analysis set (FAS).</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI seroprot. (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI serocon. (2nd vacc) N=46,48,46,50,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="66" upper_limit="91"/>
                    <measurement group_id="O2" value="38" lower_limit="65" upper_limit="90"/>
                    <measurement group_id="O3" value="36" lower_limit="64" upper_limit="89"/>
                    <measurement group_id="O4" value="41" lower_limit="69" upper_limit="91"/>
                    <measurement group_id="O5" value="41" lower_limit="72" upper_limit="94"/>
                    <measurement group_id="O6" value="35" lower_limit="58" upper_limit="85"/>
                    <measurement group_id="O7" value="36" lower_limit="62" upper_limit="88"/>
                    <measurement group_id="O8" value="28" lower_limit="49" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprot. (2nd vacc) N=46,48,46,50,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="74" upper_limit="95"/>
                    <measurement group_id="O2" value="43" lower_limit="77" upper_limit="97"/>
                    <measurement group_id="O3" value="42" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O4" value="46" lower_limit="81" upper_limit="98"/>
                    <measurement group_id="O5" value="44" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O6" value="45" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O7" value="44" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O8" value="32" lower_limit="59" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI serocon. (3rd vacc) N=25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="55" upper_limit="91"/>
                    <measurement group_id="O2" value="17" lower_limit="46" upper_limit="85"/>
                    <measurement group_id="O3" value="19" lower_limit="48" upper_limit="84"/>
                    <measurement group_id="O4" value="27" lower_limit="60" upper_limit="90"/>
                    <measurement group_id="O5" value="15" lower_limit="39" upper_limit="79"/>
                    <measurement group_id="O6" value="13" lower_limit="41" upper_limit="85"/>
                    <measurement group_id="O7" value="11" lower_limit="22" upper_limit="59"/>
                    <measurement group_id="O8" value="15" lower_limit="39" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI seroprot. (3rd vacc) N=25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="69" upper_limit="97"/>
                    <measurement group_id="O2" value="21" lower_limit="64" upper_limit="95"/>
                    <measurement group_id="O3" value="22" lower_limit="59" upper_limit="92"/>
                    <measurement group_id="O4" value="31" lower_limit="73" upper_limit="97"/>
                    <measurement group_id="O5" value="18" lower_limit="51" upper_limit="88"/>
                    <measurement group_id="O6" value="18" lower_limit="68" upper_limit="99"/>
                    <measurement group_id="O7" value="17" lower_limit="41" upper_limit="78"/>
                    <measurement group_id="O8" value="20" lower_limit="59" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio After Two Doses of the Seasonal eTIV_a Influenza Vaccine (Strain H1N1)</title>
        <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
        <time_frame>21 days after second vaccination (day 43)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After Two Doses of the Seasonal eTIV_a Influenza Vaccine (Strain H1N1)</title>
          <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
          <population>Full analysis set (FAS)</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="9.54" upper_limit="23"/>
                    <measurement group_id="O2" value="13" lower_limit="8.43" upper_limit="20"/>
                    <measurement group_id="O3" value="14" lower_limit="8.82" upper_limit="21"/>
                    <measurement group_id="O4" value="6.77" lower_limit="4.46" upper_limit="10"/>
                    <measurement group_id="O5" value="12" lower_limit="7.81" upper_limit="18"/>
                    <measurement group_id="O6" value="10" lower_limit="6.69" upper_limit="16"/>
                    <measurement group_id="O7" value="6.23" lower_limit="4.03" upper_limit="9.61"/>
                    <measurement group_id="O8" value="11" lower_limit="6.76" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Immunogenicity Results After the Booster Vaccination Against the MF59-eH5N1 Influenza Vaccine Mixed Extemporaneously With the Seasonal eTIV_a Influenza Vaccine</title>
        <description>Booster was given on day 382; seroconversion: negative pre-vaccination serum (HI titer &lt;10, SRH area ≤ 4 mm^2)/positive post-vaccination titer (HI titer ≥10) or at least 50% increase in SRH area; Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.
The number of subjects achieving seroconversion or significant increase and seroprotection were calculated at day 382.</description>
        <time_frame>21 days after booster vaccination (day 403)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Immunogenicity Results After the Booster Vaccination Against the MF59-eH5N1 Influenza Vaccine Mixed Extemporaneously With the Seasonal eTIV_a Influenza Vaccine</title>
          <description>Booster was given on day 382; seroconversion: negative pre-vaccination serum (HI titer &lt;10, SRH area ≤ 4 mm^2)/positive post-vaccination titer (HI titer ≥10) or at least 50% increase in SRH area; Seroprotection is defined as a HI titer ≥40 and a SRH area ≥25 mm^2.
The number of subjects achieving seroconversion or significant increase and seroprotection were calculated at day 382.</description>
          <population>Full analysis set (FAS)</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotection (HI) _MF59-H5N1 (N=35, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="57" upper_limit="88"/>
                    <measurement group_id="O2" value="16" lower_limit="43" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (HI)_MF59-H5N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="54" upper_limit="85"/>
                    <measurement group_id="O2" value="15" lower_limit="39" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection (SRH)_MF59-H5N1 (N=35, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="39" upper_limit="74"/>
                    <measurement group_id="O2" value="7" lower_limit="12" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (SRH)_MF59-H5N1 (N=35, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="42" upper_limit="76"/>
                    <measurement group_id="O2" value="10" lower_limit="21" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection (HI) - eTIV_a (H1N1) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O2" value="24" lower_limit="80" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (HI) - eTIV_a (H1N1) N=39, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="31" upper_limit="66"/>
                    <measurement group_id="O2" value="10" lower_limit="21" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection (HI) - eTIV_a (H3N2) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="25" lower_limit="86" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (HI) - eTIV_a (H3N2) N=39, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="19" upper_limit="52"/>
                    <measurement group_id="O2" value="5" lower_limit="7" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection (HI) - eTIV_a (B) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="73" upper_limit="97"/>
                    <measurement group_id="O2" value="18" lower_limit="51" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion (HI) - seTIV_a (B) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="7" upper_limit="34"/>
                    <measurement group_id="O2" value="4" lower_limit="5" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio After Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccine (Strain H3N1)</title>
        <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
        <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccine (Strain H3N1)</title>
          <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
          <population>Full analysis set (FAS)</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI GMR (2nd vacc) N= 46,48,46,50,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="4.01" upper_limit="9.01"/>
                    <measurement group_id="O2" value="9.72" lower_limit="6.54" upper_limit="14"/>
                    <measurement group_id="O3" value="9.34" lower_limit="6.22" upper_limit="14"/>
                    <measurement group_id="O4" value="11" lower_limit="7.54" upper_limit="16"/>
                    <measurement group_id="O5" value="11" lower_limit="7.26" upper_limit="16"/>
                    <measurement group_id="O6" value="10" lower_limit="6.92" upper_limit="15"/>
                    <measurement group_id="O7" value="11" lower_limit="7.25" upper_limit="16"/>
                    <measurement group_id="O8" value="7.54" lower_limit="4.96" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI GMR (3rd vacc) N= 25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="9.56" upper_limit="29"/>
                    <measurement group_id="O2" value="10" lower_limit="6.04" upper_limit="18"/>
                    <measurement group_id="O3" value="17" lower_limit="9.86" upper_limit="28"/>
                    <measurement group_id="O4" value="18" lower_limit="11" upper_limit="29"/>
                    <measurement group_id="O5" value="8.92" lower_limit="5.12" upper_limit="16"/>
                    <measurement group_id="O6" value="11" lower_limit="5.8" upper_limit="20"/>
                    <measurement group_id="O7" value="17" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O8" value="13" lower_limit="7.64" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio After Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccine (Strain B)</title>
        <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
        <time_frame>21 days after second and third vaccinations (day 43 and day 403)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Alone</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Concomitant+Mixed</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O3">
            <title>Concomitant+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O4">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O5">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
          <group group_id="O6">
            <title>Mixed+MF59-eH5N1</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O7">
            <title>MF59-eH5N1+eTIV_a</title>
            <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O8">
            <title>eTIV_a+MF59-eH5N1</title>
            <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After Two or Three Vaccinations of the Seasonal eTIV_a Influenza Vaccine (Strain B)</title>
          <description>For each vaccine group, the least squares GMRs were calculated for the haemagglutination inhibition (HI) results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 1.</description>
          <population>Full analysis set (FAS)</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI GMR (2nd vacc) N= 46,48,46,50,48,48,47,43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.85" upper_limit="17"/>
                    <measurement group_id="O2" value="13" lower_limit="9.01" upper_limit="19"/>
                    <measurement group_id="O3" value="10" lower_limit="6.94" upper_limit="15"/>
                    <measurement group_id="O4" value="10" lower_limit="7.22" upper_limit="15"/>
                    <measurement group_id="O5" value="17" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O6" value="8.77" lower_limit="6.07" upper_limit="13"/>
                    <measurement group_id="O7" value="10" lower_limit="6.97" upper_limit="15"/>
                    <measurement group_id="O8" value="8.0" lower_limit="5.44" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI GMR (3rd vacc) N= 25,25,28,35,25,20,28,25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" lower_limit="5.86" upper_limit="13"/>
                    <measurement group_id="O2" value="5.47" lower_limit="3.64" upper_limit="8.22"/>
                    <measurement group_id="O3" value="7.95" lower_limit="5.37" upper_limit="12"/>
                    <measurement group_id="O4" value="7.17" lower_limit="5.05" upper_limit="10"/>
                    <measurement group_id="O5" value="5.29" lower_limit="3.51" upper_limit="8"/>
                    <measurement group_id="O6" value="5.1" lower_limit="3.22" upper_limit="8.06"/>
                    <measurement group_id="O7" value="4.17" lower_limit="2.82" upper_limit="6.18"/>
                    <measurement group_id="O8" value="4.26" lower_limit="2.84" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio After the Booster Vaccination Against the MF59-eH5N1 Influenza Vaccine Mixed Extemporaneously With the Seasonal eTIV_a Influenza Vaccine</title>
        <description>For each vaccine group, the least squares GMRs were calculated for the HI and SRH results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 382 for all time points for the booster dose.</description>
        <time_frame>21 days after booster vaccination (day 403)</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Mixed</title>
            <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
          </group>
          <group group_id="O2">
            <title>Mixed + Mixed</title>
            <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After the Booster Vaccination Against the MF59-eH5N1 Influenza Vaccine Mixed Extemporaneously With the Seasonal eTIV_a Influenza Vaccine</title>
          <description>For each vaccine group, the least squares GMRs were calculated for the HI and SRH results for each time point of the study, as well as the associated 95% confidence intervals. GMR was calculated over day 382 for all time points for the booster dose.</description>
          <population>Full analysis set (FAS)</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI (MF59-H5N1) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="6.99" upper_limit="25"/>
                    <measurement group_id="O2" value="7.14" lower_limit="3.4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SRH (MF59-H5N1) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" lower_limit="3.59" upper_limit="6.63"/>
                    <measurement group_id="O2" value="2.77" lower_limit="1.93" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI (eTIV_a, H1N1) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" lower_limit="3.05" upper_limit="7.73"/>
                    <measurement group_id="O2" value="2.61" lower_limit="1.51" upper_limit="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI (eTIV_a, H3N2) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="1.83" upper_limit="3.76"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.44" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI (eTIV_a, B) N=35, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="1.55" upper_limit="2.48"/>
                    <measurement group_id="O2" value="1.94" lower_limit="1.47" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events and serious adverse events were collected for 20 months (the duration of the study).</time_frame>
      <desc>the number of subjects included here are from the safety population and not the enrolled population as disclosed in the Demography and Study Termination sections.</desc>
      <group_list>
        <group group_id="E1">
          <title>Concomitant Alone</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="E2">
          <title>Concomitant+Mixed</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="E3">
          <title>Concomitant+MF59-eH5N1</title>
          <description>1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="E4">
          <title>Mixed</title>
          <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="E5">
          <title>Mixed + Mixed</title>
          <description>dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382</description>
        </group>
        <group group_id="E6">
          <title>Mixed+MF59-eH5N1</title>
          <description>1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="E7">
          <title>MF59-eH5N1+eTIV_a</title>
          <description>1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
        <group group_id="E8">
          <title>eTIV_a+MF59-eH5N1</title>
          <description>1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspiration bronchial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-Cell small lymphocytic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Ependymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

